Biotime is thrilled to share the resounding success of its participation in EXPOMED 2024, the prestigious international trade fair held in Turkey. The event proved to be an exceptional platform for Biotime to engage with professionals, researchers, and healthcare providers from around the world, while showcasing its impressive range of fluorescent, chemiluminescent, and electrochemical products. EXPOMED 2024 surpassed expectations, delivering unparalleled opportunities for knowledge sharing and fostering collaborations with new partners. Biotime seized the chance to connect with industry experts and explore avenues for innovation and advancement in the medical field. Throughout the event, the company's product captivated the attention of both new and existing clients. The success of Biotime's participation can be attributed to its dedicated sales team, which delivered comprehensive and professional product introductions. Clients were provided with in-depth insights into the features and benefits of Biotime's state-of-the-art offerings, ensuring an exceptional exhibition experience. Looking ahead, Biotime eagerly anticipates its next venture at Hospitalar 2024 in Brazil. With great enthusiasm, the company is preparing to meet its esteemed sponsors and industry peers. Hospitalar 2024 promises to be another exceptional opportunity for Biotime to showcase its innovative products, foster new connections, and explore further avenues for growth. Biotime remains committed to delivering groundbreaking solutions that contribute to advancements in healthcare. The company's exceptional performance at EXPOMED 2024 solidifies its position as a leading player in the industry, and it looks forward to continuing its mission of transforming patient care through innovation and collaboration.

Biotime is excited to extend an invitation to our esteemed sponsors to visit our booth at EXPOMED Istanbul. As one of the premier medical exhibitions in Eurasia, this event presents a unique opportunity to explore our cutting-edge products and stay abreast of the latest advancements in medical technology.   Taking place at the Tüyap Fair and Congress Center in Istanbul from April 25th to 27th, 2024, EXPOMED serves as a platform for healthcare professionals to engage in face-to-face meetings with representatives from leading companies in the industry. Biotime will be located at Hall 8, booth number 838-5, where our team will showcase a range of innovative solutions, including Chemiluminescence Immunoassay, Fluorescent Immunoassay, High Performance Liquid Chromatography, and Infectious Disease Solution.   By visiting our booth, attendees will have the opportunity to personally experience the cutting-edge technologies and advancements provided by Biotime. Our team will be available at all times to provide comprehensive and detailed information about our products, deliver engaging and informative product demonstrations, and address any questions or inquiries attendees may have.   Event Details:   Exhibition: EXPOMED Istanbul 2024 Booth No.: Hall 8 838-5 Date: April 25th - 27th, 2024 Venue: Tüyap Fair and Congress Center, Istanbul   We look forward to all sponsors to mark their calendars and make plans to visit the Biotime booth at EXPOMED Istanbul.   About Biotime:   Biotime is a leading provider of Point-of-Care Testing (POCT) solutions, dedicated to delivering rapid and accurate diagnostic capabilities to healthcare professionals. With a focus on innovation, Biotime offers a comprehensive range of products, including Chemiluminescence Immunoassay, Fluorescent Immunoassay, High Performance Liquid Chromatography, and Infectious Disease Solution. By leveraging cutting-edge technologies, Biotime aims to improve patient outcomes and enhance the efficiency of healthcare delivery.

February 5-8, 2024 - Medlab Middle East 2024, the premier exhibition for laboratory products and services in the Middle East, kicked off at the Dubai World Trade Centre with great fanfare. Clinical laboratory product manufacturers from around the world showcased their latest instruments, equipment, and cutting-edge solutions to global peers and visitors.   As a leading manufacturer specializing in the research, development, and production of in vitro diagnostic reagents and instruments, Biotime made a splendid appearance at booth Z2.A39, unveiling its new chemiluminescence immunoassay analyzer, CLi-1600.   Biotime proudly demonstrated China's technological prowess. During the exhibition, we showcased multiple product lines including immunofluorescence, chemiluminescence, and rapid test, attracting a large number of attendees and receiving unanimous praise and recognition.   Our International Marketing team fully engaged with participants, fostering in-depth discussions and collaborations. Every member of our international marketing team received high praise from customers for their product explanations and demonstrations. Biotime is committed to providing satisfactory solutions to every customer.   This exhibition also allowed us to establish closer partnerships with industry peers, laying a solid foundation for future development.   Through Medlab, we not only showcased Biotime's innovative technologies and leading products to attendees but also engaged in profound exchanges with industry experts, scholars, and colleagues, collectively driving progress and development in the field of medical diagnostics.   In the years ahead, Biotime will steadfastly maintain our team spirit and commitment to innovation, as we continue to drive forward the progress of medical diagnostics and make meaningful contributions to human health.

Biotime, a leading manufacturer of advanced diagnostic reagents and instruments, is delightJoin Biotime at Medlab Middle East 2024: Discover the Latest Innovations in Diagnostic Solutionsed to announce its participation in Medlab Middle East 2024. As one of the world's largest specialized laboratory exhibition, Medlab Middle East attracts professionals worldwide, establishing itself as the premier international trade platform for medical laboratory equipment and diagnostics in the Middle East region. About Medlab Medlab Middle East has gained global recognition for its excellence and is endorsed by the Scientific Equipment and Furniture Association (SEFA) of the United States. As an integral part of the Arab Health Exhibition and Congress, Medlab Middle East brings together attendees and exhibitors from over 51 countries to showcase the latest advancements in laboratory equipment and diagnostic products. Spanning an impressive 30,000 square meters at the Dubai International Convention and Exhibition Centre, the exhibition consistently receives high satisfaction ratings from exhibitors and visitors, offering significant business opportunities in the Middle East healthcare market. During the exhibition Biotime will showcase its cutting-edge chemiluminescence analyzer - CLi-1600. Additionally, we will feature our renowned Fluorescent Immunoassay Series, Colloidal Gold Tests, and Urine Test Strips, providing comprehensive Point-of-Care Testing (POCT) solutions. For more information about Biotime, please visit our booth at Z2.A39. About Biotime Biotime is a leading provider of advanced diagnostic reagents and instruments. The company is dedicated to improving healthcare outcomes with a focus on innovation, quality, and customer satisfaction.

Biotime's Dengue Ag&Ab Combo Rapid Test has undergone rigorous evaluation and has met the standards required for Thai Medical Device Import Licensing. This significant achievement underscores Biotime's unwavering commitment to delivering cutting-edge diagnostic solutions to the global healthcare community. The acquisition of Thai Medical Device Import Licensing marks a pivotal milestone for Biotime. With this regulatory approval, Biotime can now expand the availability of its Dengue Ag&Ab Combo Rapid Test in Thailand, effectively addressing the pressing need for accurate and timely dengue diagnosis in the region. Dengue, a prevalent mosquito-borne disease, poses a significant health challenge worldwide. Biotime acknowledges the urgency of combatting this disease and is proud to contribute to the collective effort. By providing healthcare professionals with access to our Dengue Ag&Ab Combo Rapid Test, we empower them to make informed decisions for effective dengue management and patient care. The Dengue Ag&Ab Combo Rapid Test offers a comprehensive solution for the qualitative detection of NS1 antigen and IgG/IgM antibodies to all four serotypes of the Dengue virus. With results available in just minutes, our rapid lateral flow immunoassay enables early detection and prompt treatment, crucial for successful patient outcomes. Furthermore, Biotime's Dengue Ag&Ab Combo Rapid Test distinguishes between primary and secondary infections, aiding healthcare professionals in tailoring appropriate interventions. This differentiation is vital in optimizing patient management strategies and allocating healthcare resources efficiently. Biotime remains steadfast in its mission to create a healthier and safer world. Through continued innovation, dedication, and collaboration with the global healthcare community, we strive to make a meaningful impact in the fight against infectious diseases. Biotime is a leading provider of innovative diagnostic solutions, committed to improving global healthcare outcomes. With a focus on infectious diseases, Biotime develops cutting-edge rapid tests that deliver accurate results in a timely manner. By harnessing the power of technology and scientific advancements, Biotime aims to create a healthier and safer world for all.

Successful Conclusion of the MEDICA Exhibition in Germany   From November 13th to 16th, 2023, the 55th edition of MEDICA, the International Trade Fair for Hospital and Medical Technology, took place as scheduled at the Düsseldorf Exhibition Center in Germany. Biotime showcased its platform-based testing solutions, including immunofluorescence, chemiluminescence, and colloidal gold, at this prestigious event.     During the exhibition, Biotime's multi-platform testing products made a stunning appearance, attracting numerous attendees to stop and visit.       Biotime’s HLC-100 Fully Automated HbA1c Analyzer provides a prompt, reliable solution for diabetes diagnosis. It utilizes the high performance liquid chromatography (HPLC) analytical technique, a gold standard that helps detect glycosylated hemoglobin (HbA1c) with superior precision. Its capability to measure HbA1c, HbF, and other hemoglobin fragments enables clinicians to make quick, accurate diagnoses, thus facilitating timely treatment for the patient.   √ 12 sample positions √ HbA1c analysis in 2 minutes √ The gold standard for the detection HbA1c     CLi-1600 semi-automated device which quantifies biomarkers for thyroid disease, inflammation, cardiac diseases, fertility, diabetes, bone metabolism, anemia, and health check by analyzing human serum, plasma and whole blood.   √ Lyophilized Powder: 2-30°C √ Robust：16 Channels √ Compact：312mm*382mm*345 mm √ Homogeneous: No need washing √ Accurate: CV ≦ 5% √High Sensitivity: Nano-scaled particles   The FLI-100 Analyzer represents an elevated standard at Biotime, in pursuing simplicity, quality assurance, and data security for healthcare organizations. Designed for quantitative in vitro assay determinations, the Biotime FLI-100 analyzer was purposefully built to support immunoassay analysis for a broad range of applications – from biomarker work to infectious disease testing. The analyzer’ s immunofluorescence technology yields high sensitivity, reliable, and reproducible results for convenient point-of-care diagnostic testing on one device with a small footprint.   √ Easy-to-use √ Improved mobility √ Efficient and cost-effective √ Automatic self-check system √ Connectivity √ Extensive support     As a high-tech enterprise specializing in the research, development, production, and sales of in-vitro diagnostic reagents and instruments, Biotime adheres to a pragmatic and innovative approach, with a mission to apply science and technology to serve health. The company is committed to providing high-quality products and services to global users and contributing to the global medical and health industry with the strength of Biotime!

Biotime cordially invites you to join us at the highly anticipated 55th edition of the MEDICA International Hospital and Medical Equipment Exhibition, taking place from November 13th to 16th, 2023, at the renowned Dusseldorf Exhibition Center in Germany. This prestigious event will gather healthcare professionals from across the globe, providing a platform to explore the latest advancements in in-vitro diagnostics, including Biotime's biochemistry luminescence, immunofluorescence, and colloidal gold series. Event Overview:   MEDICA, the International Hospital and Medical Equipment Exhibition in Dusseldorf, Germany, is globally recognized as the largest and most comprehensive medical exhibition of its kind. It showcases a wide range of medical devices, supplies, and equipment, alongside medical communication information technology, medical furniture, medical facility construction technology, and medical equipment management solutions. Throughout the exhibition, there will be numerous seminars, lectures, discussions, and demonstrations, providing attendees with valuable insights into the latest industry trends and technological innovations.   The exhibition serves as a vital platform for industry professionals to connect and exchange knowledge, paving the way for advancements and innovations in the field of medical devices and diagnostic technologies. Visitors will have the opportunity to interact closely with experts from Biotime, specializing in biochemistry luminescence, immunofluorescence, colloidal gold, and other cutting-edge products. Discover their latest offerings and solutions firsthand.   MEDICA 2023 promises to be an exceptional event, fostering collaboration and exploration of the forefront of medical equipment and diagnostic technology. Join us as we collectively strive to advance and innovate in the IVD industry.

Biotime, an innovative healthcare manufacturer, is pleased to announce its remarkable presence and achievements at three prominent international medical exhibitions.   The company showcased its cutting-edge products at the South Africa International Medical Equipment Exhibition - Africa Health (see figure 1.), the Hospital Expo in Indonesia (see figure 2.) and Health Asia in Pakistan (see figure 3.). Through these events, Biotime engaged in fruitful discussions with global customers and partners, exploring new technologies and products in the ever-evolving healthcare industry.   Biotime's immunoassay fluorescence products stole the spotlight at the exhibitions, attracting significant attention from attendees. The products' user-friendly operation and exceptional accuracy in delivering results impressed scholars, experts, and distributors alike. Visitors had the invaluable opportunity to interact with Biotime's technical team, gaining profound insights into the technological features and application advantages of the company's immunoassay fluorescence platform. (figure1. Africa Health 2023) (figure 2.Hospital Expo 2023) (figure 3.Health Asia 2023) At present, Biotime's immunoassay fluorescence testing platform covers a wide range of series, including cardiovascular, inflammation, hormones, thyroid function, diabetes, and renal injury. The platform boasts an impressive turnaround time, with results available in as fast as 3 minutes. Additionally, it seamlessly integrates with various instruments, such as the single-channel BIOT-YG-I Immunoassay Fluorescence Analyzer, the six-channel FLI-600 Dry Fluorescence Immunoassay Analyzer, and the FLI-4000 Fully Automated Dry Fluorescence Immunoassay Analyzer. This versatility effectively caters to the diverse testing needs of different medical institutions.   We are elated with with the success and acclaim garnered at these international medical exhibitions. Our groundbreaking immunoassay fluorescence products have captured the industry's interest, and we take immense pride in our contribution to advancing healthcare technologies on a global scale. Our dedication to driving progress in the medical industry remains steadfast, as we continue to develop solutions that enhance patient care.